Adherence to cysteamine in nephropathic cystinosis: A unique electronic monitoring experience for a better understanding. A prospective cohort study: CrYSTobs
Authors:
- Segolene GaillardSGSegolene Gaillard
- Laurent RocheLRLaurent Roche
- Sandrine LemoineSLSandrine Lemoine
- Georges DeschênesGDGeorges Deschênes
- Denis MorinDMDenis Morin
- Christine Vianey-SabanCVChristine Vianey-Saban
- Cécile Acquaviva-BourdainCACécile Acquaviva-Bourdain
- Bruno RanchinBRBruno Ranchin
- Justine BacchettaJBJustine Bacchetta
- Behrouz KassaiBKBehrouz Kassai
- Patrice NonyPNPatrice Nony
- Eurielle BodénanEBEurielle Bodénan
- 9 September 2020
- journal article
- research article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 36 (3) , 581-589
Abstract
Introduction In nephropathic cystinosis (NC), adherence to cysteamine remains challenging; poor adherence is worsening the disease progression with a decline of kidney function and increase of extrarenal morbidities. Our objective was to describe adherence to cysteamine in NC patients, using electronic monitoring systems. Methods Patients with confirmed NC, aged > 4 years and receiving oral cysteamine (short acting or delayed release formulation as standard of care) from 3 French reference centers, were included. Adherence to treatment was primarily assessed as the percentage of days with a good adherence score, adherence score rating from 0 (poor) to 2 (good). A descriptive analysis was performed after 1-year follow-up. Results Seventeen patients (10 girls, median age: 13.9 (5.4–33.0) years) were included. Median age at diagnosis was 17.0 (3.0–76.9) months and age at start of cysteamine was 21.0 (15.5–116.3) months. Median daily dose of cysteamine was 1.05 (0.55–1.63) g/m2/day. Over the year, the median percentage of days with a good adherence score was 80 (1–99)% decreasing to 68 (1–99)% in patients > 11 years old. The median of average number of hours covered by treatment in a day was 22.5 (6.1–23.9) versus 14.9 (9.2–20.5) hours for delayed release versus short acting cysteamine. Conclusion Our data are the first describing a rather good adherence to cysteamine, decreasing in adolescents and adults. We described a potential interest of the delayed release formulation. Our data highlight the need for a multidisciplinary approach including therapeutic education and individualized approaches in NC patients transitioning to adulthood. Graphical abstractKeywords
Funding Information
- PHRC 2009
This publication has 25 references indexed in Scilit:
- Halitosis in cystinosis patients after administration of immediate-release cysteamine bitartrate compared to delayed-release cysteamine bitartrateMolecular Genetics and Metabolism, 2012
- Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adultsKidney International, 2012
- Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patientsOrphanet Journal of Rare Diseases, 2011
- Strict cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosisPediatric Nephrology, 2005
- A new reversed‐phase liquid chromatographic/tandem mass spectrometric method for analysis of underivatised amino acids: evaluation for the diagnosis and the management of inherited disorders of amino acid metabolismRapid Communications in Mass Spectrometry, 2005
- Treatment of cystinosis: Simple in principle, difficult in practiceThe Journal of Pediatrics, 2004
- Long-term follow-up of well-treated nephropathic cystinosis patientsThe Journal of Pediatrics, 2004
- CystinosisNew England Journal of Medicine, 2002
- Aspects moléculaires des tubulopathiesArchives de Pédiatrie, 2002
- Cystinosis. Intracellular cystine depletion by aminothiols in vitro and in vivo.Journal of Clinical Investigation, 1976